An observational study in IBD, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Helse Stavanger HF · Observational
The study aims at studying the outcomes of a protocol-based handling of newly diagnosed Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a descriptive study and no hypothesis is predefined.
Cytokine studies, QoL and fatigue assessment will be included for hypothesis-generating purposes.
none considered needed
1,460 studies on the registry are indexed under Inflammatory Bowel Diseases; 437 are open to participants now.
This study's planned enrollment of 700 is above the median of 139 across 645 observational studies indexed under Inflammatory Bowel Diseases.
Browse Inflammatory Bowel Diseases studies →Helse Stavanger HF is the lead sponsor of 93 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All newly diagnosed IBD patients (Crohns and Ulcerative colitis) within Stavanger Univ Hospital catchment area
Exclusion Criteria:
Clinical efficacy of IBD drug therapy
Endoscopic, clinical and biochemical response
Time frame: 5 years
Fatigue in patients with coeliac disease - substudy
Fatigue severity and prevalence at diagnosis and after one year of gluten free diet
Time frame: 1 year
Fatigue in IBD
Fatigue severity and prevalence at diagnosis and during follow-up
Time frame: 5 years
IBD and the intestinal microbiome
Microbiome/eukaryome profiles associated with disease activity and treatment response from diagnosis and during follow-up
Time frame: 5 years
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Stavanger HF